ZA200102942B - Aryl-{4-fluoro-4-[(2-pyrid-2-ylethylamino)methyl]-1-peperidyl}-methanone derivatives as 5-HT1 receptor agonists. - Google Patents
Aryl-{4-fluoro-4-[(2-pyrid-2-ylethylamino)methyl]-1-peperidyl}-methanone derivatives as 5-HT1 receptor agonists. Download PDFInfo
- Publication number
- ZA200102942B ZA200102942B ZA200102942A ZA200102942A ZA200102942B ZA 200102942 B ZA200102942 B ZA 200102942B ZA 200102942 A ZA200102942 A ZA 200102942A ZA 200102942 A ZA200102942 A ZA 200102942A ZA 200102942 B ZA200102942 B ZA 200102942B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- compounds
- fluoro
- pharmaceutically acceptable
- Prior art date
Links
- -1 2-pyrid-2-ylethylamino Chemical group 0.000 title claims abstract description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title description 3
- 239000000018 receptor agonist Substances 0.000 title description 3
- 229940044601 receptor agonist Drugs 0.000 title description 3
- 102000035038 5-HT1 receptors Human genes 0.000 title description 2
- 108091005478 5-HT1 receptors Proteins 0.000 title description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 229910052801 chlorine Chemical group 0.000 claims abstract description 6
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 6
- 239000011737 fluorine Chemical group 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000000460 chlorine Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 230000008447 perception Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 2
- QCDYYCPFZKCJPC-UHFFFAOYSA-N (3,4-dichlorophenyl)-[4-fluoro-4-[(2-pyridin-2-ylethylamino)methyl]piperidin-1-yl]methanone Chemical compound C1CN(C(=O)C=2C=C(Cl)C(Cl)=CC=2)CCC1(F)CNCCC1=CC=CC=N1 QCDYYCPFZKCJPC-UHFFFAOYSA-N 0.000 claims 1
- JWRHCECOADNULM-UHFFFAOYSA-N (3-chlorophenyl)-[4-fluoro-4-[(2-pyridin-2-ylethylamino)methyl]piperidin-1-yl]methanone Chemical compound C1CN(C(=O)C=2C=C(Cl)C=CC=2)CCC1(F)CNCCC1=CC=CC=N1 JWRHCECOADNULM-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000000324 neuroprotective effect Effects 0.000 abstract description 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 42
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 239000000556 agonist Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 9
- 229960002495 buspirone Drugs 0.000 description 9
- 230000002295 serotoninergic effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000003291 dopaminomimetic effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XQEHIFNQHDMQJY-UHFFFAOYSA-N 1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidine-4-carbaldehyde Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC(F)(C=O)CC1 XQEHIFNQHDMQJY-UHFFFAOYSA-N 0.000 description 3
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MRTJHZXTEXDQIU-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]methanone Chemical compound C1CC(CO)(F)CCN1C(=O)C1=CC=C(F)C(Cl)=C1 MRTJHZXTEXDQIU-UHFFFAOYSA-N 0.000 description 2
- MJZVPLUKMNAGMO-UHFFFAOYSA-N 1-(3,4-dichlorobenzoyl)-4-fluoropiperidine-4-carbaldehyde Chemical compound C1CC(F)(C=O)CCN1C(=O)C1=CC=C(Cl)C(Cl)=C1 MJZVPLUKMNAGMO-UHFFFAOYSA-N 0.000 description 2
- PCUQVUNZXHOVLW-UHFFFAOYSA-N 4-fluoro-4-[(2-pyridin-2-ylethylamino)methyl]piperidine-1-carbaldehyde Chemical class C=1C=CC=NC=1CCNCC1(F)CCN(C=O)CC1 PCUQVUNZXHOVLW-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
- OKRDKUVSYZJNBU-UHFFFAOYSA-N (3,4-dichlorophenyl)-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]methanone Chemical compound C1CC(CO)(F)CCN1C(=O)C1=CC=C(Cl)C(Cl)=C1 OKRDKUVSYZJNBU-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9812660A FR2784378B1 (fr) | 1998-10-09 | 1998-10-09 | Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200102942B true ZA200102942B (en) | 2002-05-02 |
Family
ID=9531367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200102942A ZA200102942B (en) | 1998-10-09 | 2001-04-10 | Aryl-{4-fluoro-4-[(2-pyrid-2-ylethylamino)methyl]-1-peperidyl}-methanone derivatives as 5-HT1 receptor agonists. |
Country Status (14)
Country | Link |
---|---|
US (1) | US6448268B1 (zh) |
EP (1) | EP1119564B1 (zh) |
JP (1) | JP2003514764A (zh) |
CN (1) | CN1160348C (zh) |
AT (1) | ATE229951T1 (zh) |
AU (1) | AU761122B2 (zh) |
BR (1) | BR9914331A (zh) |
CA (1) | CA2346506C (zh) |
DE (1) | DE69904626T2 (zh) |
DK (1) | DK1119564T3 (zh) |
ES (1) | ES2187215T3 (zh) |
FR (1) | FR2784378B1 (zh) |
WO (1) | WO2000021953A1 (zh) |
ZA (1) | ZA200102942B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2840900B1 (fr) * | 2002-06-18 | 2005-02-25 | Pf Medicament | Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
FR2852244B1 (fr) * | 2003-03-13 | 2007-09-07 | Pf Medicament | Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene |
EP3260452A1 (en) * | 2016-06-24 | 2017-12-27 | Neurolixis | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
FR2755967B1 (fr) * | 1996-11-21 | 1999-01-29 | Pf Medicament | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments |
-
1998
- 1998-10-09 FR FR9812660A patent/FR2784378B1/fr not_active Expired - Fee Related
-
1999
- 1999-10-07 ES ES99970390T patent/ES2187215T3/es not_active Expired - Lifetime
- 1999-10-07 JP JP2000575859A patent/JP2003514764A/ja not_active Withdrawn
- 1999-10-07 BR BR9914331-3A patent/BR9914331A/pt not_active Application Discontinuation
- 1999-10-07 CN CNB998131091A patent/CN1160348C/zh not_active Expired - Fee Related
- 1999-10-07 CA CA002346506A patent/CA2346506C/fr not_active Expired - Fee Related
- 1999-10-07 DK DK99970390T patent/DK1119564T3/da active
- 1999-10-07 DE DE69904626T patent/DE69904626T2/de not_active Expired - Lifetime
- 1999-10-07 US US09/807,102 patent/US6448268B1/en not_active Expired - Lifetime
- 1999-10-07 EP EP99970390A patent/EP1119564B1/fr not_active Expired - Lifetime
- 1999-10-07 AU AU59905/99A patent/AU761122B2/en not_active Ceased
- 1999-10-07 AT AT99970390T patent/ATE229951T1/de not_active IP Right Cessation
- 1999-10-07 WO PCT/FR1999/002401 patent/WO2000021953A1/fr active IP Right Grant
-
2001
- 2001-04-10 ZA ZA200102942A patent/ZA200102942B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US6448268B1 (en) | 2002-09-10 |
FR2784378A1 (fr) | 2000-04-14 |
EP1119564B1 (fr) | 2002-12-18 |
EP1119564A1 (fr) | 2001-08-01 |
ES2187215T3 (es) | 2003-05-16 |
FR2784378B1 (fr) | 2000-12-29 |
BR9914331A (pt) | 2001-06-26 |
AU5990599A (en) | 2000-05-01 |
WO2000021953A1 (fr) | 2000-04-20 |
DE69904626D1 (en) | 2003-01-30 |
ATE229951T1 (de) | 2003-01-15 |
AU761122B2 (en) | 2003-05-29 |
DE69904626T2 (de) | 2003-10-23 |
DK1119564T3 (da) | 2003-04-07 |
CN1325396A (zh) | 2001-12-05 |
CA2346506C (fr) | 2009-01-13 |
JP2003514764A (ja) | 2003-04-22 |
CN1160348C (zh) | 2004-08-04 |
CA2346506A1 (fr) | 2000-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5834493A (en) | Indole derivatives as 5-HT1A and/or 5-HT2 ligands | |
CN1934091B (zh) | 治疗神经变性障碍的咪唑化合物 | |
US6498168B2 (en) | Muscarinic antagonists | |
EP0906301B1 (en) | Benzofuryl derivatives and their use | |
CN102241667B (zh) | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 | |
EP1870405A1 (en) | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | |
HU228356B1 (en) | Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds | |
JPH0819123B2 (ja) | 1−インドリルアルキル−4−(アルコキシピリミジニル)ピペラジン | |
JPS6112685A (ja) | クロマン類及びクロメン類,それらの製法及びそれらを含む医薬組成物 | |
KR20110025226A (ko) | 신규한 테트라메틸 치환된 피페리딘 유도체 및 모노아민 신경전달물질 재흡수 억제제로서의 이의 용도 | |
CZ20022319A3 (cs) | Substituovaná fenylpiperazinová sloučenina a farmaceutický prostředek, který ji obsahuje | |
ZA200500467B (en) | Novel aryl-{4-halo-4-[(heteroarylmethylamino)methyl]-piperidin-1-yl}methanone derivatives methods for production and use thereof as medicaments | |
SK2992000A3 (en) | Tetrahydro gamma-carbolines | |
JPH037257A (ja) | ピリジン誘導体及びそれを有効成分とする向精神剤 | |
US6242448B1 (en) | Trisubstituted-oxazole derivatives as serotonin ligands | |
US6448268B1 (en) | Aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-ht1 receptor antagonists | |
JPH01135772A (ja) | 1−置換イミダゾール−5−カルボン酸及びカルボン酸誘導体の製造方法 | |
MXPA01003586A (en) | Aryl-{4-fluoro-4- [(2-pyridin-2-yl- ethylamino)-methyl]- piperidin-1- yl}-methanone derivatives as 5-ht1 receptor antagonists | |
JPH0733744A (ja) | インダゾール誘導体およびその塩 | |
JPH02503007A (ja) | 抗精神病性γ‐カルボリンN‐オキシド | |
JPH069622A (ja) | 2−アルコキシキノキサリン誘導体、その製造法およびその用途 | |
JPH05201978A (ja) | N−(4,7−ジメトキシ−2−インダニル)−1−(フェニルカルボニル)−n−プロピル−4−ピペリジンメタンアミン誘導体、その製造法および医薬への応用 | |
JPS60214784A (ja) | 複素環式化合物 | |
US5185338A (en) | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof | |
JPH0641079A (ja) | ピリジン誘導体 |